Literature DB >> 10997724

Protein phosphatase activity is increased in a rat model of long-term beta-adrenergic stimulation.

P Bokník1, M Fockenbrock, S Herzig, J Knapp, B Linck, H Lüss, F U Müller, T Müller, W Schmitz, F Schröder, J Neumann.   

Abstract

We tested the hypothesis that altered phosphorylation of Ca2+ regulatory proteins contributes to contractile anomalies in cardiac hypertrophy. Cardiac hypertrophy was induced in rats by chronic s.c. administration of isoproterenol (Iso, 2.4 mg/kg/day) via osmotic minipumps. On day 2 of Iso treatment the expression of atrial natriuretic factor was increased, time of relaxation in isolated papillary muscles shortened and protein expression of phospholamban (PLB) and sarcoplasmic reticulum Ca2+-ATPase reduced. In addition, the phosphorylation state of PLB at serine-16 and threonine-17 was decreased from (arbitrary units) 2.3+/-0.3 to 1.1+/-0.2 and from 4.1+/-0.6 to 2.1+/-0.2, respectively. This was not accompanied by altered activity of PLB-phosphorylating protein kinases (protein kinase A or Ca2+/calmodulin-dependent protein kinase II), whereas the activity of types 1 and 2A protein phosphatases (PP1 and -2A respectively) was enhanced from 1.1+/-0.08 to 1.71+/-0.13 nmol/mg/min. Iso treatment did not alter the PP1/PP2A activity ratio and 1 nmol/l okadaic acid, a concentration which completely blocks the catalytic subunit of PP2A, inhibited about 40% of total PP activity in all groups studied. These data indicate that the activity of both PP1 and PP2A were increased. All effects of Iso treatment were abolished by co-administration of propranolol (29.7 mg/kg/day). It is concluded that dephosphorylation of PLB is due to enhanced activity of PP1 and PP2A. We suggest that chronic beta-adrenergic stimulation, which occurs in human cardiac hypertrophy and failure, can lead to increased activity of PPs. This may contribute to altered contractile responses in the hypertrophied heart.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10997724     DOI: 10.1007/s002100000283

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  28 in total

1.  Contractile responses to selective phosphodiesterase inhibitors following chronic beta-adrenoreceptor activation.

Authors:  Oleg E Osadchii; Angela J Woodiwiss; Gavin R Norton
Journal:  Pflugers Arch       Date:  2005-12-17       Impact factor: 3.657

Review 2.  The relationship between the MMP system, adrenoceptors and phosphoprotein phosphatases.

Authors:  A Rietz; Jp Spiers
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 3.  Abnormal Ca(2+) cycling in failing ventricular myocytes: role of NOS1-mediated nitroso-redox balance.

Authors:  Mark T Ziolo; Steven R Houser
Journal:  Antioxid Redox Signal       Date:  2014-08-07       Impact factor: 8.401

4.  Activated expression of cardiac adenylyl cyclase 6 reduces dilation and dysfunction of the pressure-overloaded heart.

Authors:  Yasuo Sugano; N Chin Lai; Mei Hua Gao; Amy L Firth; Jason X-J Yuan; Wilbur Y W Lew; H Kirk Hammond
Journal:  Biochem Biophys Res Commun       Date:  2010-12-30       Impact factor: 3.575

5.  Okadaic acid induces matrix metalloproteinase-9 expression in fibroblasts: crosstalk between protein phosphatase inhibition and β-adrenoceptor signalling.

Authors:  A Rietz; Y Volkov; A Davies; M Hennessy; J P Spiers
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

6.  Beta-adrenergic adaptation in paediatric idiopathic dilated cardiomyopathy.

Authors:  Shelley D Miyamoto; Brian L Stauffer; Stephanie Nakano; Rebecca Sobus; Karin Nunley; Penny Nelson; Carmen C Sucharov
Journal:  Eur Heart J       Date:  2012-07-26       Impact factor: 29.983

Review 7.  Regulation of cardiac excitation and contraction by p21 activated kinase-1.

Authors:  Yunbo Ke; Ming Lei; R John Solaro
Journal:  Prog Biophys Mol Biol       Date:  2009-01-24       Impact factor: 3.667

8.  Regulation of gap-junction protein connexin 43 by beta-adrenergic receptor stimulation in rat cardiomyocytes.

Authors:  Yi Xia; Kai-Zheng Gong; Ming Xu; You-Yi Zhang; Ji-Hong Guo; Yao Song; Ping Zhang
Journal:  Acta Pharmacol Sin       Date:  2009-07       Impact factor: 6.150

9.  Inhibitor-2 prevents protein phosphatase 1-induced cardiac hypertrophy and mortality.

Authors:  Nicole Brüchert; Nirmala Mavila; Peter Boknik; Hideo A Baba; Larissa Fabritz; Ulrich Gergs; Uwe Kirchhefer; Paulus Kirchhof; Marek Matus; Wilhelm Schmitz; Anna A DePaoli-Roach; Joachim Neumann
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-08-08       Impact factor: 4.733

Review 10.  Role of protein phosphatase-1 inhibitor-1 in cardiac physiology and pathophysiology.

Authors:  Persoulla Nicolaou; Roger J Hajjar; Evangelia G Kranias
Journal:  J Mol Cell Cardiol       Date:  2009-05-27       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.